Actively Recruiting
Study of OxiblumeCoQ10 Ralivia Treatment for Men Aged 18-50 With Chronic ProstatitisChronic Pelvic Pain Syndrome in a Double-Blind Placebo-Controlled Trial
Led by G.Gennimatas General Hospital · Updated on 2026-06-05
100
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the treatment efficacy and safety of OxiblumeCoQ10 Ralivia therapy for men with Chronic ProstatitisChronic Pelvic Pain Syndrome CPCPPS. This condition involves discomfort or pain in the pelvic or perineal area lasting at least three months within the last six months. The trial is a double-blind, placebo-controlled, randomized clinical study coordinated by the 1st Urology Department at Aristotle University of Thessaloniki, Greece. Participants will be randomly assigned to one of two groups the active treatment group receiving one pill of Ralivia daily for three months, or the placebo group receiving a daily placebo pill for the same period. The study includes two follow-up visits at 6 and 12 weeks after starting treatment, during which clinical symptoms and various health parameters will be assessed. During the study, participants will complete questionnaires assessing pain, urinary symptoms, erectile function, and quality of life. Blood tests measuring inflammatory markers and prostate-specific antigen will be performed, and adverse events will be monitored throughout. The primary outcome is the change in the pain score from baseline to 12 weeks. Total participation lasts at least 12 weeks with close monitoring of symptoms and safety.
CONDITIONS
Brief Title
Oxiblume:CoQ10 (Ralivia) Therapy for Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS)
Research Team
I
IOANNIS MYKONIATIS, Professor
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here